protein

FPRP/PTGFRN Protein, Cynomolgus (HEK293, His)

HY-P77467

5 μg;10 μg;50 μg;100 μg

45;75;200;340 USD

FPRP/PTGFRN Protein, Cynomolgus (HEK293, His)

proteins

HEK293

5 μg;10 μg;50 μg;100 μg

45;75;200;340 USD

Prostaglandin F2 receptor inhibitor (PTGFRN) is a type I transmembrane Ig superfamily cell adhesion molecule. PTGFRN is overexpressed in glioblastoma and promotes cell growth and radiation resistance through the PI3K-AKT signaling pathway. PTGFRN is involved in adipocyte maturation, muscle regeneration, tumor angiogenesis, metastasis, inhibition of follicle-stimulating hormone and luteinizing hormone secretion, and plasmodium infection. FPRP/PTGFRN Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived FPRP/PTGFRN protein, expressed by HEK293 , with C-His labeled tag.

Cynomolgus

Prostaglandin F2 receptor inhibitor (PTGFRN) is a type I transmembrane Ig superfamily cell adhesion molecule that is upregulated in several cancers, including glioma. PTGFRN manifests as a gene fusion (PTGFRN-NOTCH2) in colorectal cancer and as a point mutation in small-cell lung cancer. It interacts with tetranins (CD9 and CD81), integrins, Ezrin-Radixin-Moesin (ERM) proteins, and gamma-secretase to regulate cell adhesion and migration. It has also been found to be involved in adipocyte maturation, muscle regeneration, tumor angiogenesis, metastasis, inhibition of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) secretion, and plasmodium infection. PTGFRN is overexpressed in glioblastoma and promotes cell growth and radiation resistance through the PI3K-AKT signaling pathway [1] [2] .

Prostaglandin F2 receptor negative regulator; CD315; CD9P-1

Greater than 95% as determined by reducing SDS-PAGE

Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization.

Room temperature in continental US; may vary elsewhere.